Patients with multiple sclerosis (MS) treated with the rituximab had a significantly lower risk of relapse than MS patients receiving standard treatment. This has been shown in a phase 3 clinical trial by researchers at Karolinska Institutet and Danderyd Hospital in Sweden published in The Lancet Neurology. Rituximab is not approved as an MS drug, but has...